natgillin/translations-raw huggingface dataset:
Patienter med HR+ (ER og/eller PgR-positive) tumorer skulle have modtaget og have haft sygdomsprogression efter mindst en endokrin behandling (adjuverende eller metastatisk) eller skulle have sygdom, som den behandlende læge mente var uegnet til endokrin behandling. 
Patients with HR+ (ER and/or PgR positive) tumours must have received and progressed on at least one endocrine therapy (adjuvant or metastatic) or had disease that the treating physician believed to be inappropriate for endocrine therapy.
Der blev også observeret en fordel hos patienter med BRCA1/2-vildtype/varianter af usikker betydning (BRCA1/2 wt/VUS), selvom dette var af mindre størrelsesorden. 
A benefit was also observed in patients with BRCA1/2 wild-type/variants of uncertain significance (BRCA1/2 wt/VUS), although of a lesser magnitude.
Olaparib hæmmede UGT1A1 in vitro, men PBPK-simulationer tyder på, at dette ikke er af klinisk betydning. 
Olaparib inhibited UGT1A1 in vitro, however, PBPK simulations suggest this is not of clinical importance.
gBRCA1/2-mutationsstatus skal fastslås af et erfarent laboratorium ved hjælp af en valideret testmetode. 
gBRCA1/2 mutation status should be determined by an experienced laboratory using a validated test method.
Patienter med hormonreceptor (HR)-positiv brystcancer bør også have haft progression på eller efter tidligere endokrin behandling eller anses for værende uegnede til endokrin behandling. 
Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.
Din læge har udskrevet Lynparza kapsler til dig. 
Your doctor has prescribed Lynparza capsules for you.
• Det vides ikke, om Lynparza går over i modermælken. 
• It is not known whether Lynparza passes into breast milk.
Der er ikke noget krav om BRCA1/2-test før anvendelse af Lynparza til vedligeholdelsesbehandling af recidiverende EOC, FTC eller PPC til patienter, som udviser helt eller delvist respons på platinbaseret behandling. 
There is no requirement for BRCA1/2 testing prior to using Lynparza for the maintenance treatment of relapsed EOC, FTC or PPC who are in a complete or partial response to platinum-based therapy.
Studier med humane knoglemarvsceller viste også, at direkte eksponering for olaparib kan medføre toksicitet overfor knoglemarvsceller i ex vivo-analyser. 
Studies using human bone marrow cells also showed that direct exposure to olaparib can result in toxicity to bone marrow cells in ex vivo assays.
Behandlingen fortsatte indtil radiologisk progression af den underliggende sygdom, uacceptabel toksicitet eller i op til 2 år. 
Treatment was continued until radiological progression of the underlying disease, unacceptable toxicity or for up to 2 years.
• lavt antal hvide blodlegemer (lymfopeni), som kan nedsætte din evne til at bekæmpe infektioner, og som kan være forbundet med feber 
• low white blood cell count (lymphopenia) which may decrease your ability to fight infection and may be associated with fever
I et fertilitetsstudie med hunrotter fik rotterne doser indtil implantation, og selvom der blev observeret forlænget østral periode hos nogle dyr, sås der ingen påvirkning af parringsaktivitet og drægtighedsrate. 
In a female fertility study where rats were dosed until implantation, although extended oestrus was observed in some animals, mating performance and pregnancy rate was not affected.
Dosisafbrydelserne forekom hyppigst i de første 3 måneder, og dosisreduktionerne i de første 3-6 måneder af behandlingen. 
Dose interruptions occurred most frequently in the first 3 months and dose reductions in the first 3-6 months of treatment.
Den mest almindelige histologiske type var serøs (96 %), og endometrioid histologi blev rapporteret hos 2 % af patienterne. 
The most common histological type was serous (96%), endometrioid histology was reported in 2% of the patients.
• Lægen vil fortælle dig, hvor mange tabletter Lynparza, du skal tage. 
• Your doctor will tell you how many tablets of Lynparza to take.
Patienter, som tager Lynparza, kan opleve træthed, asteni eller svimmelhed. 
Patients who take Lynparza may experience fatigue, asthenia or dizziness.
Anæmi og anden hæmatologisk toksicitet var generelt af lav grad (CTCAE grad 1 eller 2), men der var rapporter om CTCAE grad 3 og højere forekomster. 
Anaemia and other haematological toxicities were generally low grade (CTCAE grade 1 or 2), however, there were reports of CTCAE grade 3 and higher events.
En piperazin-3-ol-del med åben ring og to monooxygenerede metabolitter (hver ~10 %) var de største cirkulerende dele, hvor den ene monooxygenerede metabolit også var den største metabolit i ekskretet (henholdsvis 6 % og 5 % af radioaktiviteten i urinen og fæces). 
A ring-opened piperazin-3-ol moiety, and two mono-oxygenated metabolites (each ~10%) were the major circulating components, with one of the mono-oxygenated metabolites also being the major metabolite in the excreta (6% and 5% of the urinary and faecal radioactivity, respectively).
Deltagelse krævede ikke bevis for BRCA1/2-mutation (BRCA-mutationsstatus blev for nogle patienter bestemt retrospektivt). 
Enrolment did not require evidence of BRCA1/2 mutation (BRCA mutation status for some patients was determined retrospectively).
• telithromycin, clarithromycin, erythromycin - anvendes til bakterieinfektioner 
• telithromycin, clarithromycin, erythromycin - used for bacterial infections
Antal tidligere kemoterapilinjer mod metastatisk brystcancer (%) 
Missing Number of prior lines of chemotherapy for metastatic breast cancer (%)
35 % af patienterne havde interval debulking kirurgi, og af disse rapporterede 82 % ingen makroskopisk residualsygdom. 
Interval debulking surgery was performed in 35% of the patients and of these 82% had no macroscopic residual disease reported.
Brug af Lynparza sammen med drikke 
Lynparza with drink
Som efterfølgende behandling, modtog 0,5 % og 8 % af patienterne en PARP-inhibitor i henholdsvis behandlings- og komparator-armene; henholdsvis 29 % og 42 % af patienterne fik efterfølgende platinbehandling. 
As subsequent therapy, 0.5% and 8% of patients received a PARP inhibitor in the treatment and comparator arms, respectively; 29% and 42% of patients, respectively, received subsequent platinum therapy.
Der er blevet vist induktion af CYP1A2, CYP2B6 og CYP3A4 in vitro, hvor CYP2B6 er den, der mest sandsynligt induceres i klinisk relevant omfang. 
Induction of CYP1A2, 2B6 and 3A4 has been shown in vitro with CYP2B6 being most likely to be induced to a clinically relevant extent.
• Doserne i Lynparza kapsler og tabletter er ikke de samme. 
• The doses of Lynparza capsules and tablets are not the same.
Kemoterapi (N = 97) Olaparib 300 mg to gange dagligt (N = 205) 
Chemotherapy (N = 97) Olaparib 300 mg twice daily (N = 205)
Meget almindelig Hoste a, dyspnø 
Very common Cough a, Dyspnoea
63 % af patienterne havde primær debulking kirurgi, og af disse havde størstedelen (75 %) ingen makroskopisk residualsygdom. 
Sixty-three percent (63%) of the patients had upfront debulking surgery and of these the majority (75%) had no macroscopic residual disease.
Der blev ikke observeret nogen statistisk signifikante forskelle mellem olaparib og placebo blandt patientrapporterede symptomer eller helbredsrelateret livskvalitet som målt ved forbedrings- og forværringsrater i FACT/NCCN Ovarian Symptom Index (FOSI), Trial Outcome Index (TOI) og Functional Analysis of Cancer Therapy-Ovarian total score (FACT-O total). 
No statistically significant differences were observed between olaparib and placebo in patient reported symptoms or HRQoL as measured by improvement and worsening rates in the FACT/NCCN Ovarian Symptom Index (FOSI), Trial Outcome Index (TOI) and Functional Analysis of Cancer TherapyOvarian total score (FACT-O total).
Lynparza kan, baseret på dets virkningsmekanisme (PARP-hæmning), forårsage føtal skade, når det administreres til en gravid kvinde. 
Based on its mechanism of action (PARP inhibition), Lynparza could cause foetal harm when administered to a pregnant woman.
Antal patienter i risikogruppen Olaparib 300 mg tablet to gange dagligt 
Number of patients at risk Olaparib 300 mg twice daily tablet
93 % af patienterne blev randomiseret inden for 8 uger af deres sidste dosis platinbaserede kemoterapi. 
Ninety three percent (93%) of patients were randomised within 8 weeks of their last dose of platinum-based chemotherapy.
• Kapselindhold: lauroylmacrogol-32-glycerider. 
• Capsule content: lauroyl macrogol-32 glycerides.
Patienterne skal tidligere have været i behandling med et antracyklin og et taxan til (neo)adjuverende eller metastatisk regi, medmindre patienterne ikke var egnede til disse behandlinger (se pkt. 
Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1).
Der var 389 patienter med germline BRCA1/2m og 2 med somatisk BRCA1/2m i SOLO1. 
There were 389 patients who were germline BRCA1/2m and 2 who were somatic BRCA1/2m in SOLO1.
Gentagen behandling med olaparib var ikke tilladt efter progression på olaparib. 
Retreatment with olaparib was not permitted following progression on olaparib.
Der var ingen påvist sygdom ved indtræden i studiet (CR), defineret af investigator som intet radiologisk bevis på sygdom og cancerantigen 125 (CA-125) inden for det normale interval, hos 73 % og 77 % af patienterne i henholdsvis olaparib- og placeboarmene. 
There was no evidence of disease at study entry (CR), defined by the investigator as no radiological evidence of disease and cancer antigen 125 (CA-125) within normal range, in 73% and 77% of patients in the olaparib and placebo arms, respectively.
Derfor kan Lynparza tages uden hensyntagen til fødevarer (se pkt. 
Consequently, Lynparza may be taken without regard to food (see section 4.2).
OS-analyse hos patienter uden forudgående kemoterapi for metastatisk brystcancer indikerede fordele for disse patienter med en HR på 0,45 (95 % CI 0,27-0,77), mens for yderligere behandlingslinjer overskred HR 1. 
OS analysis in patients with no prior chemotherapy for metastatic breast cancer indicated benefit in these patients with a HR of 0.45 (95% CI 0.27-0.77), while for further lines of therapy HR exceeded 1.
56 filmovertrukne tabletter (7 blisterkort). 
56 film-coated tablets (7 blisters).
• allergiske reaktioner (fx nældefeber, vejrtrækningsbesvær eller synkebesvær, svimmelhed, som alle er tegn og symptomer på overfølsomhedsreaktioner). 
• allergic reactions (e.g. hives, difficulty breathing or swallowing, dizziness which are signs and symptoms of hypersensitivity reactions).
Det anbefales at udføre passende klinisk monitorering af patienter, der får CYP3A-substrater med en snæver terapeutisk margin samtidig med olaparib. 
Appropriate clinical monitoring is recommended for patients receiving CYP3A substrates with a narrow therapeutic margin concomitantly with olaparib.
I normale celler er homolog rekombinationsreparation (HRR), som kræver funktionelle BRCA1- og -2-gener, effektiv til at reparere disse DNA-DSB'er. 
In normal cells, homologous recombination repair (HRR), which requires functional BRCA1 and 2 genes, is effective at repairing these DNA DSBs.
Der findes ingen dyrestudier om udskillelse af olaparib i modermælk. 
There are no animal studies on the excretion of olaparib in breast milk.
Hos rotter blev der også bemærket minimale degenerative virkninger på mave-tarm-kanalen. 
In rats, minimal degenerative effects on gastrointestinal tract were also noted.
Efter oral administration af olaparib via kapselformuleringen er absorptionen hurtig, typisk med højeste plasmakoncentrationer opnået mellem 1 til 3 timer efter dosering. 
Following oral administration of olaparib via the capsule formulation, absorption is rapid with peak plasma concentrations typically achieved between 1 to 3 hours after dosing.
Patienterne bør påbegynde behandling med Lynparza senest 8 uger efter afslutning af den sidste dosis af det platinholdige regime. 
Patients should start treatment with Lynparza no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
• Lægen vil fortælle dig, hvor mange kapsler Lynparza, du skal tage. 
• Your doctor will tell you how many capsules of Lynparza to take.
Sekundære endepunkter omfattede PFS2; OS, TDT, TFST, TSST og HRQoL. 
Secondary efficacy endpoints included PFS2; OS, TDT, TFST, TSST; and HRQoL.
I stedet for aktiveres alternative og fejlbehæftede reparationsmekanismer, såsom den klassiske ikke-homologe endesammenføjning (NHEJ), hvilket fører til øget genomisk ustabilitet. 
Instead, alternative and error-prone pathways are activated, such as the classical non-homologous end joining (NHEJ) pathway, leading to increased genomic instability.
Ovariecancer Lynparza er indiceret som monoterapi til: 
Ovarian cancer Lynparza is indicated as monotherapy for the:
PFS - DCO 30. juni 2010 
PFS - DCO 30 June 2010
I den olaparibbehandlede gruppe forblev 28,4 % af patienterne i behandlingen i ≥2 år og 14,9 % i ≥5 år. 
In the olaparib-treated group, 28.4% of patients remained on treatment for ≥2 years and 14.9% for ≥5 years.
I olaparib-armen havde 8 % med målbar sygdom et komplet respons versus 1,5 % af patienterne i komparator-armen; 74/167 (44 %) af patienterne i olaparib-armen havde et delvist respons versus 14/66 (21 %) af patienterne i kemoterapi-armen. 
In the olaparib arm 8% with measurable disease had a complete response versus 1.5% of patients in the comparator arm; 74/167 (44%) of patients in the olaparib arm had a partial response versus 14/66 (21%) of patients in the chemotherapy arm.
Kvindelige partnere til mandlige patienter skal også anvende højeffektiv antikonception, hvis de er i den fertile alder (se pkt. 
Female partners of male patients must also use highly effective contraception if they are of childbearing potential (see section 4.4).
• Du skal bruge kondom, når du har sex med en kvindelig partner, også selvom hun er gravid, mens du tager Lynparza og i 3 måneder efter at have taget den sidste dosis. 
• You must use a condom when having sex with a female partner, even if she is pregnant, while taking Lynparza and for 3 months after taking the last dose.
Dyspnø omfatter de foretrukne termer for dyspnø og funktionsdyspnø; Stomatitis omfatter de foretrukne termer for aftøs ulcus, ulceration i munden og stomatitis. 
Dyspnoea includes PTs of dyspnoea and dyspnoea exertional; Stomatitis includes PTs of aphthous ulcer, mouth ulceration and stomatitis.
Ved anvendelse af den samme analyse var den fraktion, der var bundet til surt alfa-1-glykoprotein 29 % ved 10 µg/ml med en tendens til nedsat binding ved højere koncentrationer. 
Using the same assay, the fraction bound to alpha-1 acid glycoprotein was 29% at 10 µg/mL with a trend of decreased binding at higher concentrations.
gBRCA1/2-muteret HER2-negativ metastatisk brystcancer: 
gBRCA1/2-mutated HER2-negative metastatic breast cancer:
In vitro var den humane plasmaproteinbinding af olaparib dosisafhængig; den bundne fraktion var ca. 91 % ved 1 µg/ml, faldt til 82 % ved 10 µg/ml og til 70 % ved 40 µg/ml. 
In vitro, human plasma protein binding of olaparib was dose-dependent; the fraction bound was approximately 91% at 1 µg/mL, reducing to 82% at 10 µg/mL and to 70% at 40 µg/mL.
Hyppighed for forekomsten af bivirkninger er defineret som: meget almindelig (≥ 1/10); almindelig ( 1/100 til < 1/10); ikke almindelig (≥ 1/1.000 til < 1/100); sjælden (≥ 1/10.000 til < 1/1000); meget sjælden (< 1/10.000); ikke kendt (kan ikke estimeres ud fra forhåndenværende data). 
Frequencies of occurrence of adverse reactions are defined as: very common (≥ 1/10); common ( 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1000); very rare (< 1/10,000); not known (cannot be estimated from available data).
Meget almindelig Træthed (inklusive asteni) 
Very common Fatigue (including asthenia)
• hvis du oplever nye eller forværrede symptomer på kortåndethed, hoste eller hvæsen. 
• if you experience any new or worsening symptoms of shortness of breath, coughing or wheezing.
Større omarrangeringer i BRCA1/2-generne blev detekteret hos 5,5 % (21/383) af de randomiserede patienter. 
Large rearrangements in the BRCA1/2 genes were detected in 5.5% (21/383) of the randomised patients.
--------------Placebo bd - - - - - - - - - Olaparib 400 mg bd Antal patienter i risiko: 
--------------Placebo bd - - - - - - - - - Olaparib 400 mg bd Number of patients at risk:
Blandt patienterne, der deltog i studiet med målbar sygdom (mål-læsioner ved baseline) blev der opnået en objektiv responsrate på 41 % i Lynparza-armen versus 17 % på placebo. 
Among the patients entering the trial with measurable disease (target lesions at baseline), an objective response rate of 41% was achieved in the Lynparza arm versus 17% on placebo.
Det vides ikke, om olaparib eller dets metabolitter findes i sædvæske. 
It is not known whether olaparib or its metabolites are found in seminal fluid.
Der var evidens for, at alle patienter ved baseline havde gBRCA1/2m. 
All patients had evidence of gBRCA1/2m at baseline.
Lynparza leveres i pakninger indeholdende 56 filmovertrukne tabletter (7 blisterkort med 8 tabletter i hver), eller multipakninger indeholdende 112 (2 pakninger a 56) filmovertrukne tabletter. 
Lynparza is supplied in packs containing 56 film-coated tablets (7 blisters of 8 tablets each), or multipacks containing 112 (2 packs of 56) film-coated tablets.
I stedet for aktiveres alternative og fejlbehæftede stier, såsom den ikke-homologe endesammenføjning (NHEJ)-sti, hvilket fører til øget genomisk ustabilitet. 
Instead, alternative and error-prone pathways are activated, such as the non-homologous end joining (NHEJ) pathway, leading to increased genomic instability.
Mediantiden til første forekomst af anæmi var ca. 4 uger (ca. 7 uger for bivirkninger af CTCAE grad ≥ 3). 
Median time to first onset of anaemia was approximately 4 weeks (approximately 7 weeks for CTCAE grade ≥3 events).
• Doserne i Lynparza tabletter og kapsler er ikke de samme. 
• The doses of Lynparza tablets and capsules are not the same.
Almindelig Stomatitis 
Common Stomatitis
Lynparza kan administreres til patienter med let nedsat nyrefunktion (kreatininclearance 51 til 80 ml/min) uden dosisjustering. 
Lynparza can be administered in patients with mild renal impairment (creatinine clearance 51 to 80 ml/min) with no dose adjustment.
Måneder n-olaparib n-placebo 
months n-olaparib 74 n-placebo
Lynparza påvirker i moderat grad evnen til at føre motorkøretøj og betjene maskiner. 
Lynparza has moderate influence on the ability to drive and use machines.
• lavt antal hvide blodlegemer (leukopeni eller neutropeni), som kan nedsætte din evne til at bekæmpe infektioner, og som kan være forbundet med feber. 
• low white blood cell count (leukopenia or neutropenia) which may decrease your ability to fight infection and may be associated with fever.
Må ikke sælges separat. 
Component of a multipack, not to be sold separately.
De sekundære endepunkter omfattede PFS2, OS, objektiv responsrate (ORR) og HRQoL. 
Secondary endpoints included PFS2, OS, objective response rate (ORR) and HRQoL.
Den samlede forekomst af myelodysplastisk syndrom/akut myeloid leukæmi (MDS/AML) hos patienter, som blev behandlet alene med Lynparza i kliniske studier, herunder langtidsopfølgning af overlevelse, var <1,5 %, og størstedelen af tilfældene havde dødelig udgang. 
Myelodysplastic syndrome/Acute myeloid leukaemia The overall incidence of myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML) in patients treated in clinical trials with Lynparza monotherapy, including long-term survival follow-up, was <1.5% and the majority of events had a fatal outcome.
Lynparza anvendes til behandling af en type kræft i æggestokkene, som kaldes “BRCA-muteret ovariecancer”. 
Lynparza is used for the treatment of a type of ovarian cancer called “BRCA-mutated ovarian cancer”.
• en følelse af åndenød, en følelse af ekstrem træthed, bleg hud eller hurtigt puls - dette kan være symptomer på et fald i antallet af røde blodlegemer (anæmi). 
• feeling short of breath, feeling very tired, pale skin or fast heart beat - these may be symptoms of a decrease in the number of red blood cells (anaemia).
Gennemsnit af PFS (måneder) 
Median PFS (months)
In vitro blev CYP3A4/5 påvist at være de enzymer, som primært var ansvarlige for metabolisme af olaparib (se pkt. 
In vitro, CYP3A4/5 were shown to be the enzymes primarily responsible for the metabolism of olaparib (see section 4.5).
C-olaparib til kvindelige patienter udgjorde uforandret olaparib størstedelen af den radioaktivitet, der var i kredsløb i plasma (70 %) og var den væsentligste komponent, som blev fundet i både urin og fæces (henholdsvis 15 % og 6 % af dosen). 
C-olaparib to female patients, unchanged olaparib accounted for the majority of the circulating radioactivity in plasma (70%) and was the major component found in both urine and faeces (15% and 6% of the dose, respectively).
Hvis pneumonitis bekræftes, bør behandling med Lynparza ophøre, og patienten bør få passende behandling. 
If pneumonitis is confirmed, Lynparza treatment should be discontinued and the patient treated appropriately.
Forekomsten af dosisafbrydelser, -reduktioner og -seponeringer på grund af en bivirkning var henholdsvis 34,6 %, 25,7 % og 5,9 %. 
The incidence of dose interruptions, reductions and discontinuations due to an adverse event was 34.6%, 25.7% and 5.9%, respectively.
Pædiatrisk population Der er ikke udført nogen studier for at undersøge olaparibs farmakokinetik hos pædiatriske patienter. 
Paediatric population No studies have been conducted to investigate the pharmacokinetics of olaparib in paediatric patients.
Hvad Lynparza anvendes til 
What Lynparza is used for
Inden for den BRCA-muterede population var sygdomskontrolraten ved 24 uger henholdsvis 57 % og 24 % for patienter i olaparib- og placebogruppen. 
Within the BRCA-mutated population the disease control rate at 24 weeks was 57% and 24% for patients in the olaparib and placebo groups, respectively.
Olaparib hæmmer CYP3A4 in vitro og forventes at være en svag CYP3A-inhibitor in vivo. 
Olaparib inhibits CYP3A4 in vitro and is predicted to be a mild CYP3A inhibitor in vivo.
I den placebobehandlede gruppe forblev 8,1 % af patienterne i behandling i ≥2 år og 1,6 % i ≥5 år. 
In the placebo-treated group, 8.1% of patients remained on treatment for ≥2 years and 1.6% for ≥5 years.
Lokal eller central test af blod- eller tumorprøver for BRCA1/2-mutationer er blevet anvendt i forskellige studier. 
Local or central testing of blood or tumour samples for BRCA1/2 mutations has been used in different studies.
PR, defineret som tilstedeværelsen af målbare eller ikkemålbare læsioner ved baseline eller forhøjet CA-125, blev rapporteret hos 27 % og 23 % af patienterne i henholdsvis olaparib og placebo-armene. 
PR, defined as the presence of any measurable or non-measurable lesions at baseline or elevated CA-125, was reported in 27% and 23% of patients in the olaparib and placebo arms, respectively.
Administration samtidig med fødevarer satte hastigheden ned (tmax forsinket med 2,5 timer og Cmax reduceret med ca. 21 %), men påvirkede ikke signifikant omfanget af absorption af olaparib (AUC øget med 8 %). 
Co-administration with food slowed the rate (tmax delayed by 2.5 hours and Cmax reduced by approximately 21%) but did not significantly affect the extent of absorption of olaparib (AUC increased 8%).
Omkring en fjerdedel af de placebobehandlede patienter i den BRCA-muterede sub-gruppe (14/62; 22,6 %) fik en efterfølgende PARP-inhibitor. 
Approximately a quarter of placebo-treated patients in the BRCA-mutated subgroup (14/62; 22.6%) received a subsequent PARP inhibitor.
Kvalme blev generelt rapporteret meget tidligt med første opståen inden for den første måned af behandling med Lynparza hos størstedelen af patienterne. 
Nausea was generally reported very early, with first onset within the first month of Lynparza treatment in the majority of patients.
Det vides ikke, om Lynparza overføres til sæd. 
It is not known whether Lynparza passes into semen.